abstract: The serum and cerebrospinal fluid (CSF) of 8 @entity1 with @entity2055 , 6 of whom also had eye @entity910 believed to be @entity1319 , were found to contain a highly specific antineuronal antibody we call anti-Ri. Seven of the 8 @entity1 also had or developed @entity5 : @entity0 in 5, @entity420 in an axillary lymph node in 1, and @entity6887 in 1. Four @entity1 presented with the @entity16 ; the @entity5 was diagnosed first in the other 4. Immunohistochemical studies using serum or CSF from all 8 @entity1 revealed a highly specific antibody interaction with central nervous system neuronal nuclei but not with glial or other cells; the titer ranged from 1:5,000 to 1:320,000 in serum and from 1:2,000 to 1:16,000 in CSF. Biotinylated IgG from the patients' serum reacted with the @entity5 of 3 of 4 patients with anti-Ri antibody but not with @entity0 from patients without anti-Ri antibody. Immunoblots against cerebral cortex neuronal extracts identified protein antigens of 55-kd and 80-kd relative molecular mass. Serum titers by immunoblot ranged from 1:500 to more than 1:40,000 and CSF titers, from 1:10 to 1:2,000. The relative amount of anti-Ri was always higher in CSF than in serum. The antibody was not present in sera from normal individuals; @entity1 with @entity0 without @entity1319 ; other @entity1 with @entity1319 ; or @entity1 with other @entity8231 related to @entity5344 . We conclude that the presence of anti-Ri antibody identifies a subset of @entity1 with @entity2055 and @entity1319 ( @entity1319 ) who usually suffer from breast or other gynecological @entity5 ; the antibody when present is a useful marker for an underlying @entity5 .

title: Anti-Ri: an antibody associated with paraneoplastic XXXX and @entity0 .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancers', 'carcinoma of the breast', 'breast cancer']

entities_list: @entity5344 :: ('MESH:D061325', 'Disease') :: ['breast, ovarian, or small-cell lung cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'malignancy', 'tumors']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological disorder']

entities_list: @entity6887 :: ('MESH:D005185', 'Disease') :: ['carcinoma of the fallopian tube']

entities_list: @entity910 :: ('MESH:D004409', 'Disease') :: ['movement abnormalities']

entities_list: @entity1319 :: ('MESH:D015835', 'Disease') :: ['eye movement disorders', 'opsoclonus']

entities_list: @entity8231 :: ('MESH:D010257', 'Disease') :: ['paraneoplastic syndromes']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

entities_list: @entity2055 :: ('MESH:D001259', 'Disease') :: ['paraneoplastic ataxia', 'ataxia']

answer: @entity1319 :: (MESH:D015835,Disease) :: ['opsoclonus']


abstract: PURPOSE: To assess the efficacy and of iloprost in the treatment of @entity2119 . METHODS: In this prospective study, 158 @entity1 with @entity158 and/or @entity63 ulcers from 17 clinics were administered 1 ng/kg/min intravenous iloprost for 28-days. The primary endpoint was complete healing without @entity158 or major amputation at 24 weeks. The secondary endpoints were @entity158 assessment, reduction in @entity1066 area, 50% reduction of the @entity1066 size, shift in the modified SVS/ISCVS clinical status grading scale, global assessment by the investigator and an independent observer at 4 and 24 weeks. The comparisons were carried out with the initial values. The final evaluation was carried out in 150 @entity1 . RESULTS: Complete healing rate was significantly better with iloprost treatment in comparison to the initial values at 24 weeks (<0.001). The secondary endpoints; complete healing rate, @entity158 , the size of the @entity1066 , 50% reduction of the @entity1066 size, SVS/ISCVS grading scale, assessment by investigator, assessment by observer parameters were significantly better at 4 and 24 weeks (<0.001). The reduction of the @entity1066 size was significantly better when comparing 4th and 24th week values (<0.05). CONCLUSION: The results of this independent study indicate that intravenous iloprost relieves @entity63 symptoms efficiently in the acute phase @entity2119 @entity1 . Considering unsatisfactory results following surgical revascularisation and sympathectomy in @entity2119 , @entity4770 analogues might be the first line treatment as long as complete abstinence from smoking is achieved.

title: A stable XXXX analogue (iloprost) in the treatment of @entity2119 : a prospective analysis of 150 @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity4770 :: ('MESH:D011464', 'Chemical') :: ['prostacyclin']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['rest pain', 'pain']

entities_list: @entity2119 :: ('MESH:D013919', 'Disease') :: ["Buerger's disease"]

answer: @entity4770 :: (MESH:D011464,Chemical) :: ['prostacyclin']


abstract: BACKGROUND: Swimming is a relatively genotype-specific arrhythmogenic trigger for @entity26320 ( @entity9677 ). We hypothesize that mimickers of concealed @entity9677 , namely @entity1165 ( @entity1165 ), may also underlie swimming-triggered @entity299 . METHODS AND RESULTS: Between August 1997 and May 2003, 388 consecutive, unrelated @entity1 were referred specifically for LQTS genetic testing. The presence of a personal and/or family history of a near-drowning or drowning was determined by review of the medical records and/or phone interviews and was blinded to genetic test results. Comprehensive mutational analysis of the 5 LQTS-causing channel genes, @entity9677 ( @entity9677 ), @entity9678 ( @entity9678 ), @entity1788 ( @entity1788 ), @entity15500 ( @entity26321 ), and @entity26321 ( @entity26321 ), along with @entity12397 ( @entity26322 ) and targeted analysis of 18 CPVT1-associated exons in @entity23963 , was performed with the use of denaturing high-performance liquid chromatography and direct DNA sequencing. Approximately 11% (43 of 388) of the index cases had a positive swimming phenotype. Thirty-three of these 43 index cases had a "Schwartz" score (> or =4) suggesting high clinical probability of LQTS. Among this subset, 28 @entity1 (85%) were @entity9677 , 2 @entity1 (6%) were @entity9678 , and 3 were genotype negative. Among the 10 cases with low clinical probability for LQTS, 9 had novel, putative CPVT1-causing @entity23963 mutations. CONCLUSIONS: In contrast to previous studies that suggested universal @entity9677 specificity, genetic heterogeneity underlies @entity13192 that are suspected chiefly because of a near-drowning or drowning. CPVT1 and strategic genotyping of @entity23963 should be considered when @entity9677 is excluded in the pathogenesis of a swimming-triggered @entity943 syndrome.

title: Spectrum and frequency of cardiac channel defects in swimming-triggered XXXX syndromes.

entities_list: @entity1165 :: ('MESH:D017180', 'Disease') :: ['catecholaminergic polymorphic ventricular tachycardia', 'CPVT']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmia']

entities_list: @entity26322 :: ('MESH:D050030', 'Disease') :: ['Andersen-Tawil syndrome']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events']

entities_list: @entity13192 :: ('MESH:D053447', 'Disease') :: ['channelopathies']

entities_list: @entity26320 :: ('MESH:D029597', 'Disease') :: ['type 1 long-QT syndrome']

answer: @entity943 :: (MESH:D001145,Disease) :: ['arrhythmia']


abstract: Rupture of the left ventricle is one of the major lethal complications of mitral valve replacement. We have encountered 11 cases of this complication over a period of 19 years (1971, Apr.-1990, Mar.). Five of 8 cases of intraoperative @entity397 survived but no @entity1 survived a delayed @entity397 . In the @entity1 with intraoperative @entity397 external repair was performed in 6 cases, resulting in 3 survivors, two in type II and one in type I with formation of @entity1002 . For selection of surgical treatment accurate recognition of types of @entity397 is important but the location and size of the endocardial and @entity154 do not always correspond. Attempts to suture a @entity9009 on the pressure-loaded beating heart were always unsuccessful and frequently extended the tear. Repair should be accomplished with aid of cardiopulmonary bypass on the decompressed and arrested heart. Recently, we chose internal repair with arrested heart in 2 cases of type I @entity397 , that is, reopening of the left atrial closure and repair from within the cardiac chamber with removal of the prosthetic valve. Both cases survived. In conclusion, we emphasized importance of intracardiac repair with removal of the replaced prosthetic valve in left @entity9009 and III following mitral valve replacement for better exposure, more secure repair, and prevention of @entity1317 .

title: [Intracardiac repair in left XXXX following mitral valve replacement].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['epicardial defects']

entities_list: @entity9009 :: ('MESH:D018658', 'Disease') :: ['ventricular rupture', 'ventricular rupture of type I']

entities_list: @entity1317 :: ('MESH:D057772', 'Disease') :: ['injury to the circumflex artery']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['left ventricular false aneurysm']

answer: @entity9009 :: (MESH:D018658,Disease) :: ['ventricular rupture']


abstract: @entity1457 proteins (Hsp) represent proteins' groups, whose protective function, may be induced by heat, reactive @entity26 species, cytokines etc. We evaluated blood levels of @entity2284 and @entity2285 , and their relation to skeletal @entity121 and @entity32 in young tennis players before and after the conditioning camp. Blood samples were collected directly after tournament season, 3-day rest and 14-day conditioning camp that followed. @entity273 ( @entity274 ) demonstrated the highest concentration directly after tournament season, which significantly decreased at camp's end. The pro-inflammatory cytokines @entity1356 and @entity310 decreased, whereas anti-inflammatory cytokines @entity650 and @entity688 increased after 3d rest and 14d camp. @entity2284 increased after 3d rest and remained so after 14d camp, while @entity2285 decreased from baseline to camp's completion. @entity2284 and @entity2285 correlated significantly with @entity274 , @entity1356 and @entity310 . @entity121 , observed as @entity908 kinase (CK) activity changes, increased after 14d camp similarly to @entity2284 and anti-inflammatory cytokines @entity650 and @entity688 . Obtained data allows to conclude that decrease of @entity2284 and increase in pro-inflammatory cytokines could be a good indicator of overreaching. Reverse tendencies in these proteins may verify accuracy of conditioning camp. Finally, this training program caused an increase in the anti-inflammatory cytokines concentrations, improving individual status of recovery. Key PointsThe study demonstrating low grade @entity32 -induced by the tournament season in young tennis player.Three days of active rest stimulated the anti-inflammatory response via rise of @entity2284 and anti-inflammatory cytokine @entity688 .Observed decrease of blood @entity2285 may support mental recovery.Thirteen-day appropriate training program led to maintaining an immunological response balance.

title: Exercise training-induced changes in inflammatory mediators and XXXX proteins in young tennis players.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity1457 :: ('MESH:D012769', 'Disease') :: ['Heat shock']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity908 :: ('MESH:D003401', 'Chemical') :: ['creatine']

entities_list: @entity273 :: ('MESH:D006861', 'Chemical') :: ['Hydrogen peroxide']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['Muscle damage', 'muscle damage']

answer: @entity1457 :: (MESH:D012769,Disease) :: ['heat shock']


abstract: OBJECTIVES: The aim of this randomized controlled study was to cephalometrically assess possible changes in craniofacial morphology associated with long-term use of an adjustable oral-appliance compared with continuous positive airway pressure (CPAP) in @entity1 with the @entity27 ( @entity27 ). In addition, we wanted to study the relationship between these possible changes and the degree of mandibular protrusion associated with oral-appliance therapy. METHODS: Fifty-one @entity1 were randomized to oral-appliance therapy and 52 @entity1 to CPAP therapy. At baseline and after follow-up (2.3  0.2 years), a lateral cephalogram of all @entity1 was made in maximum intercuspation to determine relevant cephalometric variables. Both baseline and follow-up cephalograms were traced digitally whereupon cephalometric variables were compared. Changes in craniofacial morphology between the oral-appliance- and CPAP group were evaluated with a linear regression analysis. RESULTS: Compared with CPAP, long-term use of an oral-appliance resulted in small but significant (dental) changes. Overbite and overjet decreased, 1.0 (  1.5)mm and 1.7 (  1.6)mm, respectively. Furthermore we found a retroclination (-2.0 (  2.8)  ) of the upper incisors and a proclination (3.7 (  5.4)  ) of the lower incisors. Moreover, the lower- and total anterior facial height increased significantly, 0.8 (  1.5)mm and 0.9 (  1.4)mm, respectively. No changes in skeletal variables were found. Linear regression analysis revealed that the decrease in overbite was associated with the mean mandibular protrusion during follow-up (B=-0.029, SE=0.014, p<0.05). CONCLUSIONS: Oral-appliance therapy should be considered as a life long treatment, and there is a risk of craniofacial changes to occur. Therefore, @entity1 treated with an oral-appliance, need a thorough follow-up by a dentist or dental-specialist experienced in the field of dental sleep medicine.

title: Long-term oral-appliance therapy in XXXX : a cephalometric study of craniofacial changes.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity27 :: ('MESH:D020181', 'Disease') :: ['obstructive sleep apnea/hypopnea syndrome', 'OSAHS']

answer: @entity27 :: (MESH:D020181,Disease) :: ['obstructive sleep apnea']


abstract: BACKGROUND: To assess the safety of symptom-limited exercise testing in @entity1 with New York Heart Association class II-IV @entity712 due to @entity1002 , we investigated the frequency of all-cause fatal and nonfatal major cardiovascular (CV) events among subjects enrolled in a prospective clinical trial (HF-ACTION). We hypothesized that exercise testing would be safe, as defined by a rate for all-cause death of <0.1 per 1,000 tests and a rate of nonfatal CV events <1.0 per 1,000 tests. METHODS: Before enrollment and at 3, 12, and 24 months after randomization, subjects were scheduled to complete a symptom-limited graded exercise test with open-circuit spirometry for analysis of expired gases. To ensure the accurate reporting of exercise test-related events, we report @entity204 and nonfatal major CV events per 1,000 tests at months 3, 12, or 24 after randomization. RESULTS: A total of 2,331 subjects were randomized into HF-ACTION. After randomization, 2,037 subjects completed 4,411 exercise tests. There were no test-related @entity204 , exacerbation of @entity712 or @entity951 requiring hospitalization, @entity583 , @entity64 , or transient @entity63 attacks. There was one episode each of @entity2224 and sustained @entity1165 . There were no exercise test-related implantable cardioverter defibrillator discharges requiring hospitalization. These findings correspond to zero @entity204 per 1,000 exercise tests and 0.45 nonfatal major CV events per 1,000 exercise tests (95% CI 0.11-1.81). CONCLUSIONS: In New York Heart Association class II-IV @entity1 with severe @entity1002 , we observed that symptom-limited exercise testing is safe based on no @entity204 and a rate of nonfatal major CV events that is <0.5 per 1,000 tests.

title: Safety of symptom-limited cardiopulmonary exercise testing in @entity1 with chronic XXXX due to severe @entity1002 .

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure symptoms', 'heart failure']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['strokes']

entities_list: @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachycardia']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity2224 :: ('MESH:D014693', 'Disease') :: ['ventricular fibrillation']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarctions']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['left ventricular systolic dysfunction']

answer: @entity712 :: (MESH:D006333,Disease) :: ['heart failure']


abstract: BACKGROUND: Various surgical techniques are available in the management of @entity2869 , but controversy concerning the optimal surgical approach persists. The present study analyzes the outcome of unroofing and curettage as the primary intervention for acute and chronic @entity66 . METHODS: A total of 297 consecutive @entity1 presenting with @entity102 , @entity697 , or recurrent disease were treated with unroofing and curettage. The wound was left open to heal by secondary intention. Hospitalization, time required to resume daily activities and return to work, healing time, and recurrence rates were recorded. RESULTS: All @entity1 were discharged within the first 24 h after operation. The median period before returning to work was 3.2 +/- 1.2 days, and the mean time for wound healing was 5.4 +/- 1.1 weeks. Six @entity1 were readmitted with recurrence of the disease within the first six postoperative months. All recurrences were in @entity1 who did not follow the wound care advice and who did not come to regular weekly appointments. @entity1 with recurrence underwent repeat surgery by the same technique with good results. CONCLUSIONS: Unroofing and curettage for @entity2869 is an easy and effective technique. The vast majority of the @entity1 , including those with abscess as well as those with @entity102 , will heal with this simple procedure, after which even recurrences can be managed successfully with the same procedure. Relying on these results, we advocate unroofing and curettage as the procedure of choice in the management of @entity66 .

title: Unroofing and curettage for the treatment of acute and chronic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity697 :: ('MESH:D000208', 'Disease') :: ['acute abscess']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['pilonidal disease']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic disease']

entities_list: @entity2869 :: ('MESH:D010864', 'Disease') :: ['pilonidal sinus', 'pilonidal sinus disease']

answer: @entity66 :: (MESH:D004194,Disease) :: ['pilonidal disease']


abstract: OBJECTIVES: The aim of this study was to retrospectively evaluate @entity137 and efficacy of 3 chemoradiation regimens. METHODS: Between 1997 and 2007, 94 @entity1 with @entity418 were treated with chemoradiation in our institute. Treatment consisted of radiotherapy to 50 Gy in 25 fractions with concurrent @entity900 and @entity1487 (group A, n = 65), radiotherapy to 50.4 Gy in 28 fractions with concurrent @entity3003 and @entity1311 (group B, n = 16) or radiotherapy to 66 Gy in 33 fractions with low-dose @entity900 (group C, n = 13). @entity137 was scored according to Common Terminology Criteria version 3.0. RESULTS: Chemoradiation was planned as neoadjuvant (n = 58) or definitive (n = 36) treatment. Grade 3/4 hematological @entity137 occurred in 18 (19%) @entity1 and grade 3 nonhematologic @entity137 in 8 (9%) @entity1 . During treatment, 2 @entity1 died (1 from duodenal @entity1066 and 1 from @entity64 ). Overall, 81 (86%) @entity1 completed the planned treatment (86%, 94%, and 77% in groups A, B, and C, respectively). Clinically complete or partial response was observed in 28 of 92 (30%) @entity1 (21%, 50%, and 54% in groups A, B, and C, respectively). After clinical and radiologic response evaluation, treatment plan was changed in 14 (15%) @entity1 . A total of 45 @entity1 underwent surgery. Pathologic complete response and downstaging were seen in 12 (27%) and 34 (76%) operated @entity1 , respectively. With a median follow-up of 15 (range, 1-108) months, the 3-year survival was 41% for all @entity1 . CONCLUSION: With individual treatment planning, different regimens of chemoradiation for @entity418 resulted in acceptable rates of @entity137 and efficacy.

title: Chemoradiation for XXXX : institutional experience with three different regimens.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin']

entities_list: @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer bleeding']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel']

entities_list: @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal cancer']

entities_list: @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']

answer: @entity418 :: (MESH:D004938,Disease) :: ['esophageal cancer']


abstract: BACKGROUND AND OBJECTIVES: Novel individualized quality-of-life (IQOL) measures permit @entity1 with @entity740 ( @entity740 ) to nominate unique areas of their lives that contribute to their well-being. This study assessed for differences in domains nominated by @entity1 with @entity740 . We also examined the strength of association between (1) multidimensional health-related quality-of-life measures and IQOL and (2) psychosocial factors and IQOL. DESIGN, SETTING, @entity1 , _ MEASUREMENTS: We performed a cross-sectional study of 151 @entity1 who were undergoing peritoneal dialysis or hemodialysis or had stages 4 through 5 @entity740 . @entity1 completed the Schedule for the Evaluation of Individual Quality of Life-Direct Weighting (SEIQOL-DW), an instrument that assesses IQOL on the basis of @entity1 -identified domains. @entity1 also completed health-related quality-of-life and psychosocial health measures. RESULTS: @entity1 with @entity740 nominated many domains on the SEIQOL-DW, but family and health were the most common for all groups. @entity8 was listed more frequently by peritoneal dialysis compared with hemodialysis @entity1 or @entity1 with @entity740 (31 versus 14 versus 5%, respectively). There were no significant differences in SEIQOL-DW scores between subgroups. SEIQOL-DW scores correlated with mental well-being and inversely correlated with chronic stress and @entity308 . CONCLUSIONS: @entity1 with advanced @entity740 demonstrate compromised quality-of-life scores comparable to dialysis @entity1 . IQOL measures provide unique information that may help guide interventions that are better tailored to address @entity1 ' concerns about their well-being. These findings also suggest that renal clinics should have staff available to address psychosocial aspects of @entity1 well-being.

title: Individual quality of life in XXXX : influence of age and dialysis modality.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PARTICIPANTS']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['Kidney disease']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['CKD', 'chronic kidney disease']

answer: @entity740 :: (MESH:D051436,Disease) :: ['chronic kidney disease']


abstract: 'Very late antigen' (VLA) proteins are members of the integrin superfamily with cell-surface receptor function and are involved in the cell-cell matrix interaction. They are heterodimers with a common beta 1 chain and different alpha chains counted through @entity10503 to @entity9617 . The @entity12974 complex (alpha 2/beta 1) was found to act as collagen receptor on platelets and the @entity9617 complex (alpha 6/beta 1) as laminin receptor. Using monoclonal antibodies and an indirect immunoperoxidase method, we investigated the expression of VLA-alpha 2, VLA-alpha 6, and VLA-beta 1 chains in 20 normal colonic mucosa samples, in 20 colonic @entity652 , and in 96 @entity189 together with 10 accompanying liver @entity3 . All three proteins were expressed throughout the colonic epithelium, except for VLA-alpha 2, which was present in the cryptic gland but was absent on the mucosal surface in some cases. In general, @entity652 were strongly positive for the VLA proteins but 3 of 20 cases showed focal VLA-alpha 2-negative areas. The @entity189 revealed considerable heterogeneity of VLA-alpha 2 expression; ie, 59 @entity5 were completely positive, 35 @entity5 revealed a focal loss of antigen, and 2 cases were negative. This reduced antigen expression was statistically associated with Dukes' stage C/D (P = 0.003). VLA-alpha 6 was expressed throughout in all @entity5 . VLA-beta 1 was found extensively expressed in 77 @entity189 , partially expressed in 17 @entity189 , and was @entity189 . As compared to their @entity5 , liver @entity3 showed roughly corresponding patterns of antigen expression. The down regulation/loss of VLA proteins in a subset of epithelial @entity694 might cause a disturbed cell-cell/cell-matrix interaction that might augment the invasive property of their cells.

title: Expression of VLA-alpha 2, VLA-alpha 6, and VLA-beta 1 chains in normal mucosa and @entity694 and their liver XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumors', 'tumors']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon tumors']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas', 'absent in 2 carcinomas']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas']

answer: @entity3 :: (MESH:D009362,Disease) :: ['metastases']


abstract: Little information is available regarding effective systemic therapies for adult @entity1222 ( @entity1222 ). The Japan @entity1222 Study Group has formulated an ambulatory treatment regimen for adult @entity1 with @entity1222 . In total, 14 @entity1 (median age 43  years, range 20-70  years) with multifocal @entity1222 with biopsy-confirmed histology were enrolled. None had received cytoreductive agents for @entity1222 previously. Four had @entity262 ( @entity262 ) and ten had @entity262 ( @entity262 ) disease. All were treated with the Special C regimen, which consists of @entity5713 / @entity617 and @entity1499 with daily @entity4446 for 36  weeks. At the end of the therapeutic regimen, all @entity262 @entity1 achieved @entity66 ( @entity66 ), and six of the ten @entity262 @entity1 showed a response ( @entity66 in two, partial response in four). At the last follow-up (median 34  months), 11 @entity1 were alive ( @entity66 in eight and active disease in three). Of the three deceased, one died of @entity548 during the Special C treatment, and two of @entity281 during subsequent therapy. Although this study is limited by the small sample size, this ambulatory regimen shows signs of efficacy for adult @entity1222 . This was particularly evident for @entity1 with multifocal @entity262 , but half of those with @entity66 also benefited.

title: Therapeutic outcome of multifocal @entity1222 in adults treated with the Special C regimen formulated by the Japan XXXX Study Group.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['no active disease', 'MS disease', 'NAD']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity1222 :: ('MESH:D006646', 'Disease') :: ['Langerhans cell histiocytosis', 'LCH']

entities_list: @entity262 :: ('MESH:D034721', 'Disease') :: ['single system', 'multi system', 'SS', 'SS disease', 'MS']

entities_list: @entity4446 :: ('MESH:D015122', 'Chemical') :: ['6-mercaptopurine']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']

entities_list: @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone']

answer: @entity1222 :: (MESH:D006646,Disease) :: ['LCH']


abstract: STUDY OBJECTIVE: The gynecologic issues of adolescents with disabilities are understudied. The purpose of this study was to identify and compare the presenting complaints, treatments, and follow-up of adolescent @entity1 with @entity1467 ( @entity1467 ), @entity2438 , and @entity306 ( @entity306 ) presenting to a specialized gynecologic clinic for @entity1 with @entity717 . SETTING: Outpatient gynecology clinic. @entity1 : Forty four adolescents (<21 y); 13 with @entity1467 , 14 with @entity2438 , and 17 with @entity306 who presented to the clinic from 1999 to 2006. INTERVENTIONS: None. MAIN OUTCOME MEASURES: A retrospective review of the electronic medical records to collect data on age at presentation to clinic, ethnicity, menstrual history, chief complaint, treatment, and follow-up. RESULTS: Mean age at presentation to clinic was 15+/-3.5 years, and age of menarche was 12.5+/-2 years; age at menarche did not significantly differ between groups. The most frequent complaints were @entity548 (n=10) and mood/behavioral changes (n=6). @entity1 with @entity2438 were significantly (chi(2)=8.89, P=.012) more likely to present with behavioral issues than the other 2 groups. Initial management for the behavior issues in the @entity2438 group included nonsteroidal anti-inflammatory drugs (NSAID), oral contraceptives, and education. CONCLUSION: The most common gynecologic complaints of adolescent @entity1 with @entity1467 , @entity2438 , and @entity306 centered on menstruation and @entity1316 . @entity1 with @entity2438 were more likely to present with behavioral issues related to the onset of periods.

title: Gynecologic issues of adolescents with XXXX , @entity2438 , and @entity306 .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'girls', 'PARTICIPANTS', 'Girls']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['irregular bleeding']

entities_list: @entity1316 :: ('MESH:D019964', 'Disease') :: ['mood disorders']

entities_list: @entity1467 :: ('MESH:D004314', 'Disease') :: ['Down syndrome', 'DS']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['developmental disabilities']

entities_list: @entity306 :: ('MESH:D002547', 'Disease') :: ['cerebral palsy', 'CP']

answer: @entity1467 :: (MESH:D004314,Disease) :: ['Down syndrome']


abstract: Purpose. To describe a @entity1 with two episodes of @entity1150 and @entity5337 mutation who presented with central @entity2994 (CRVO) despite prophylactic use of @entity1229 ( @entity1229 ). Methods. A case report of a 44-year-old @entity1 with a history of recurrent @entity1150 and @entity5337 mutation was placed on lifelong prophylactic therapy with @entity1229 . The @entity1 presented with CRVO in the left eye despite therapeutic levels of @entity1229 . Results. Extensive systemic evaluation disclosed high titers for antinuclear antibody (ANA). Conclusion. Systemic anticoagulation with @entity1229 may not preclude further @entity715 episodes. In younger @entity1 presenting with @entity2994 and pre-existing multiple thrombophilic risk factors, a multidisciplinary approach is recommended to explore other therapeutic options to avoid further @entity1031 .

title: Central XXXX with therapeutic level of anticoagulation.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patients', 'patient']

entities_list: @entity5337 :: ('2153', 'Gene') :: ['Factor V Leiden', 'factor V Leiden']

entities_list: @entity2994 :: ('MESH:D012170', 'Disease') :: ['retinal vein occlusion']

entities_list: @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep venous thrombosis']

entities_list: @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic complications']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombotic']

entities_list: @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin sodium', 'Coumadin', 'warfarin']

answer: @entity2994 :: (MESH:D012170,Disease) :: ['retinal vein occlusion']


abstract: OBJECTIVE: The Melasma Area and Severity Index (MASI) and the Melasma Severity Score (MSS) are calculated on the basis of only a subjective clinical assessment. This raises the need to have an objective score, uniform in the evaluation by different clinicians. The purpose of this study was to establish if the images by Canfield Reveal Imager can be correlated to MASI score to better evaluate the clinical efficacy of @entity3785 33% peeling in the treatment of @entity1709 respect to the clinical observation. METHODS: The study was a voluntary observational study. Twenty female @entity1 affected with @entity1709 , aged between 30 and 60 years, were included in the study. Treatment with @entity3785 33% was performed once a month, for a total of four times. The dermatologist (Doc A) examined each @entity1 's @entity1709 areas using MASI score, at the face-to-face observation and at Reveal images evaluation during the first (T0) and the end point time (T4). Digital photographs were also evaluated by another experienced dermatologist (Doc B), who has never seen clinically the @entity1 before and who evaluated MASI score by Reveal images at time T0 and T4. RESULTS: Student's t-test and linear regression test were performed, showing statistically significant values comparing MASI score obtained by digital photo and MASI score obtained clinically. CONCLUSION: The monitoring of the improvement by Reveal images can optimize the treatment approach and the efficacy of same dermocosmetics procedures can be revised following standard criteria.

title: XXXX for the treatment of @entity1709 : new acquisitions for monitoring the clinical improvement.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity3785 :: ('MESH:D020156', 'Chemical') :: ['salicylic acid']

answer: @entity3785 :: (MESH:D020156,Chemical) :: ['Salicylic acid']


abstract: BACKGROUND: The optimal margin width and its influence on outcomes after hepatic resection for colorectal liver @entity3 is still controversial: a meta-analysis was conducted to analyze the impact of subcentimeter margin width on @entity1 and disease-free survival after resection. METHODS: A systematic search was performed, covering the last decade, following the Meta-analysis Of Observational Studies in Epidemiology guidelines. Relative risks (RRs) for @entity1 and disease-free survival (DFS) were calculated after resection in relationship to a margin width >1 cm (R0 > 1 cm) and between 1 mm and 1 cm (R0 < 1 cm) using the DerSimonian and Laird random-effects model. Meta-regression was applied for covariate adjustment. RESULTS: Eleven observational studies were identified involving 2823 @entity1 . Overall, 59.1% of @entity1 were R0 < 1 cm and 40.9% were R0 > 1 cm. Meta-analysis showed that compared with @entity1 with margins R0 > 1 cm, a R0 < 1 cm margin lead to decreased 1-, 3-, and 5-year DFS with a RR of 1.17 (95% confidence interval [CI] 1.07-1.27), 1.38 (95% CI 1.16-1.65), and 1.55 (95% CI 1.25-1.91), respectively, but @entity1 survival was obviously affected (P > .05 in all cases). @entity1 with margins of R0 < 1 cm differ from those with R0 > 1 cm for greater proportions of multiple @entity3 ( @entity4736 .43; 95% CI 0.25-1.61) and @entity29 ( @entity4736 .42; 95% CI 0.8-1.92). Meta-regression showed that these two covariates had a significant impact on DFS but not on @entity1 survival. CONCLUSION: A resection margin width >1 cm is desirable even if @entity1 survival is at best only slightly affected by subcentimeter margin as a consequence of a decreased DFS. The presence of multiple @entity3 and @entity7158 represent potential study selection biases that significantly decrease DFS; well-conducted, matched analyses consequently are essential to clarify the issue.

title: Impact of subcentimeter margin on outcome after hepatic resection for colorectal XXXX : a meta-regression approach.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity7158 :: ('MESH:D009378', 'Disease') :: ['synchronous bowel neoplasm']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['synchronous bowel disease']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

answer: @entity3 :: (MESH:D009362,Disease) :: ['metastases']


abstract: KEY POINTS: Physiologically relevant rodent models of @entity7936 ( @entity7936 ) that resemble the @entity1 condition are limited. Exercise training and energy restriction are first-line recommendations for the treatment of @entity7936 . Hyperphagic Otsuka Long-Evans Tokushima fatty @entity35 fed a @entity8928 high in fat, @entity969 and @entity165 for 24  weeks developed a severe @entity7936 with @entity82 phenotype. Moderate intensity exercise training and modest energy restriction provided some improvement in the histological features of @entity7936 that coincided with alterations in markers of hepatic stellate cell activation and extracellular matrix remodelling. The present study highlights the importance of lifestyle modification, including exercise training and energy restriction, in the regulation of advanced @entity409 . ABSTRACT: The incidence of @entity7936 ( @entity7936 ) is rising but the efficacy of lifestyle modifications to improve @entity7936 -related outcomes remain unclear. We hypothesized that a @entity8928 ( @entity8928 ) would induce @entity7936 in the Otsuka Long-Evans Tokushima Fatty (OLETF) @entity35 and that lifestyle modification would improve this condition. Eight-week-old Long-Evans Tokushima Otsuka (L) and OLETF (O) @entity35 consumed a control diet (10%  kcal fat, 3.5% @entity969 ) or a @entity8928 (45%  kcal fat, 17% @entity969 , 1% @entity165 ) for 24  weeks. At 20  weeks of age, additional @entity8928 -fed OLETFs were randomized to sedentary (O-SED), food restriction (O-FR;    25% kcal reduction vs. O-SED) or exercise training (O-EX; treadmill running 20  m  min(-1) with a 15% incline, 60  min  day(-1) , 5  days  week(-1) ) conditions for 12  weeks. @entity8928 induced a @entity7936 phenotype in OLETFs characterized by hepatic @entity82 (collagen 1a1 mRNA and @entity720 content), as well as elevated @entity32 and @entity1561 activity scores, and hepatic stellate cell activation (a-smooth muscle actin) compared to Long-Evans Tokushima Otsuka @entity35 . FR and EX modestly improved @entity7936 -related @entity82 markers (FR: @entity720 content, P  <  0.01; EX: collagen 1a1 mRNA, P  <  0.05; both: @entity82 score, P  <  0.01) and @entity32 (both: @entity32 score; FR: @entity3426 and @entity5 @entity39 factor a) vs. O-SED. FR reduced hepatic stellate cell activation markers (transforming growth factor-b protein and a-smooth muscle actin mRNA), whereas EX increased the hepatic stellate cell senescence marker CCN1 (P  <  0.01  vs. O-SED). Additionally, both FR and EX normalized extracellular matrix remodelling markers to levels similar to @entity8928 (P  >  0.05). Although neither EX nor FR led to complete resolution of the @entity8928 -induced @entity7936 phenotype, both independently @entity1575 via altered hepatic stellate cell activation and extracellular matrix remodelling.

title: Aerobic exercise training in the treatment of XXXX related @entity82 .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity8928 :: ('MESH:D020241', 'Disease') :: ['western diet', 'L-WD', 'WD']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity1575 :: ('MESH:D008103', 'Disease') :: ['benefitted liver fibrosis']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver disease']

entities_list: @entity7936 :: ('MESH:D005235', 'Disease') :: ['NASH', 'non-alcoholic steatohepatitis']

entities_list: @entity969 :: ('MESH:D013395', 'Chemical') :: ['sucrose']

entities_list: @entity720 :: ('CHEBI:18095', 'Chemical') :: ['hydroxyproline']

entities_list: @entity1561 :: ('MESH:D065626', 'Disease') :: ['non-alcoholic fatty liver disease']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity1561 :: (MESH:D065626,Disease) :: ['non-alcoholic fatty liver disease']


abstract: This is a case report of the anesthetic management for the hepatic resection of a metastatic @entity1823 in a @entity1 with a history of prior orthotopic liver transplantation. Of interest, the metastatic @entity1823 originated from the donor organ. The @entity1 is an 80-year-old @entity1 with multiple medical problems including a history of cryptogenic @entity82 who underwent successful orthotopic liver transplantation 9 years prior. She later presented with signs and symptoms of @entity5733 excess suggestive of a @entity5733 -producing @entity5 ( @entity1823 or @entity1911 ). Elevated urine @entity5733 levels and radiographic evidence of a @entity1823 in the transplanted liver metastatic from the donor organ confirmed the diagnosis. Radiofrequency ablation of the @entity5 and surgical resection was previously attempted without success. We describe the anesthetic management for the successful resection of the metastatic @entity99 , which was complicated by profound intraoperative @entity101 and @entity551 that necessitated the use of multiple vasoactive infusions, extensive surgical @entity190 requiring blood transfusion, and difficult glycemic control in an insulin-dependent @entity6 @entity1 . The postoperative course is also described. This unique case presented the anesthesia team with challenges specific to both surgery for hepatic resection as well as for @entity5733 -secreting @entity5 . We are not aware of any reports of @entity1823 of either donor or recipient origin involving a transplanted liver, making this the first such report to the best of our knowledge.

title: Anesthetic management for resection of XXXX metastatic from the donor organ in an orthotopic liver transplant recipient: a case report.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity5733 :: ('D002395', 'Chemical') :: ['catecholamine']

entities_list: @entity1911 :: ('MESH:D010673', 'Disease') :: ['pheochromocytoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']

entities_list: @entity1823 :: ('MESH:D010235', 'Disease') :: ['paragangliomas', 'paraganglioma']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic paraganglioma']

answer: @entity99 :: (MESH:D056486,Disease) :: ['hepatic paraganglioma']


abstract: The influence of the duration of the serum @entity53 (E2) rise before @entity1 chorionic gonadotrophin (HCG) injection on the outcome of in-vitro fertilization (IVF) cycles was investigated. Two different stimulation protocols were compared. In 218 cycles, the Norfolk protocol for stimulation with @entity1 menopausal gonadotrophin (HMG) was used (protocol A). In 235 cycles, pituitary function was suppressed by a single injection of a long-acting @entity1176 analogue (' @entity19040 microcapsules') before HMG stimulation was started (protocol B). The overall pregnancy rates were significantly higher with protocol B (22% per puncture, 21% per started cycle) than with protocol A (14% per puncture, 9% per started cycle). For each interval of E2 rise duration (5-11 days), the fertilization rates (per oocyte) and the pregnancy rates (per puncture) were evaluated. There was a clear-cut maximum of the pregnancy rates for 6 and 7 days of E2 rise (21 and 16% respectively) for protocol A. For protocol B, pregnancy rates were generally higher than for protocol A. There was also a maximum of the pregnancy rates for 6 (32%) and 7 (29%) days of E2 rise but this maximum was not as clear-cut as for protocol A. The fertilization rates showed no significant differences for each interval of E2 rise in both groups (between 63 and 89%). Therefore, it is concluded that endometrial maturity, and not the oocyte's ability for fertilization, is the most critical factor for success in IVF cycles.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Influence of the duration of the @entity53 rise on the success rate in XXXX analogue/HMG-stimulated IVF cycles.

entities_list: @entity19040 :: ('MESH:D017329', 'Chemical') :: ['Decapeptyl']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['oestradiol']

answer: @entity1176 :: (MESH:D007987,Chemical) :: ['GnRH']


abstract: Prevalence of @entity272 in @entity7289 ( @entity16695 ) is well documented. However, less is known about their joint occurrence. Information on concurrence may improve our understanding of disease pathogenesis and is required to estimate the disease burden of @entity7289 . We analysed data from 765 individuals from forest villages in the Kumba and Ngambe Health districts, Cameroon. These data were collected in 1998, as baseline data for the evaluation of the African Programme for @entity7289 Control. Concurrence of symptoms was assessed using logistic regression. @entity7289 was highly endemic in the study population (63% nodule prevalence among males aged >= 20). Considerable overall prevalences of onchocercal @entity227 ( @entity4064 or @entity1939 : 4%), troublesome itch (15%), reactive @entity272 (19%), and @entity272 (25%) were observed. The association between onchocercal @entity227 and @entity272 (OR 9.0, 95% CI 3.9-20.8) was partly explained by age and exposure to infection (OR 3.0, 95% CI 1.2-7.7). The association between troublesome itch and reactive @entity272 was hardly affected by adjustment (adjusted @entity29942 , 95% CI 4.2-11.1). Concluding, there is significant concurrence of morbidities within @entity7289 . Our results suggest a possible role of host characteristics in the pathogenesis of depigmentation and @entity227 . Further, we propose a method to deal with concurrence when estimating the @entity66 .

title: Concurrence of dermatological and ophthalmological morbidity in XXXX .

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual impairment']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['burden of disease']

entities_list: @entity16695 :: ('MESH:D015827', 'Disease') :: ['river blindness']

entities_list: @entity1939 :: ('MESH:D001766', 'Disease') :: ['blindness']

entities_list: @entity272 :: ('MESH:D012871', 'Disease') :: ['skin and eye disorders', 'skin depigmentation', 'skin disease']

entities_list: @entity4064 :: ('MESH:D015354', 'Disease') :: ['low vision']

entities_list: @entity7289 :: ('MESH:D009855', 'Disease') :: ['African onchocerciasis', 'onchocerciasis', 'Onchocerciasis']

answer: @entity7289 :: (MESH:D009855,Disease) :: ['onchocerciasis']


abstract: PURPOSE: To describe the gray-scale and color Doppler ultrasound features of uncommon (<5% prevalence) primary @entity43 . METHODS: Retrospective analysis of 98 masses in 89 @entity1 (median age: 50.4 years old, ranging from 15 to 81 years) diagnosed as having an uncommon primary @entity43 . All @entity1 had undergone transvaginal color Doppler ultrasound according to a standardized protocol prior to surgical @entity5 removal. Ultrasound features analyzed were laterality, presence of ascites, @entity5 volume, morphologic appearance (unilocular, multilocular, unilocular-solid, multilocular-solid, and solid), and color Doppler score (subjective assessment of the amount of flow as absent, scanty, moderate, or abundant). RESULTS: Pathological diagnoses included uncommon @entity5 (n = 59), germ cell @entity5 (n = 10), sex @entity4097 (n = 11), @entity242 (n = 9), and @entity706 (n = 9). @entity2971 presented in younger @entity1 (p < 0.001). @entity2971 , sex @entity4097 , @entity242 , and @entity706 were significantly more often solid as compared with @entity5 , which appeared more frequently as complex (cystic-solid) @entity5 (p < 0.001). There were no differences in color Doppler score between the various types of @entity5 . CONCLUSIONS: @entity2971 , sex @entity4097 , @entity242 , and @entity706 tend to appear as unilateral solid @entity5 . Color Doppler score is not useful for discriminating among uncommon primary @entity43 .

title: Clinical and sonographic features of uncommon primary XXXX .

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['malignant ovarian tumors', 'ovarian malignancy', 'ovarian malignancies']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcoma', 'sarcomas']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma', 'lymphomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'epithelial malignancies', 'epithelial tumors', 'tumors']

entities_list: @entity2971 :: ('MESH:D009373', 'Disease') :: ['Germ cell tumors']

entities_list: @entity4097 :: ('MESH:D013120', 'Disease') :: ['cord-stromal tumors']

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian malignancies']


abstract: BACKGROUND AND PURPOSE: Target blood pressure (BP) values for optimal cerebral perfusion after an @entity385 are still debated. We sought to examine the relationship between BP and cerebral @entity450 ( @entity450 ) during daily activities. METHODS: We studied 43 @entity1 with chronic large vessel @entity1188 in the middle cerebral artery territory (aged 64.2+/-8.94 years; at 6.1+/-4.9 years after @entity64 ) and 67 age-matched control subjects. @entity450 in middle cerebral arteries were measured during supine baseline, sitting, standing, and tilt. A regression analysis and a dynamic phase analysis were used to quantify the BP- @entity19385 relationship. RESULTS: The mean arterial pressure was similar between the groups (89+/-15 mm Hg). Baseline @entity450 were lower by approximately 30% in the @entity1 with @entity64 compared with the control subjects (P=0.0001). @entity19385 declined further with postural changes and remained lower in the @entity64 group during sitting (P=0.003), standing (P=0.003), and tilt (P=0.002) as compared with the control group. Average @entity450 on the @entity64 side were positively correlated with BP during baseline (R=0.54, P=0.0022, the slope 0.46 cm/s/mm Hg) and tilt (R=0.52, P=0.0028, the slope 0.40 cm/s/mm Hg). Regression analysis suggested that @entity19385 may increase approximately 30% to 50% at mean BP >100 mm Hg. @entity551 during the first minute of tilt or standing was independently associated with lower @entity19385 on the @entity64 side (P=0.0008). Baseline BP- @entity19385 phase shift derived from the phase analysis was smaller on the @entity64 side (P=0.0006). CONCLUSIONS: We found that @entity450 are lower in @entity1 with @entity64 and daily activities such as standing could induce hypoperfusion. @entity450 increase with mean arterial pressure >100 mm Hg. Dependency of @entity19385 on arterial pressure may have implications for BP management after @entity64 . Further prospective investigations are needed to determine the impact of these findings on functional recovery and strategies to improve perfusion pressure during daily activities after @entity385 .

title: Cerebral flow velocities during daily activities depend on blood pressure in XXXX with chronic @entity1188 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity450 :: ('MESH:D006940', 'Disease') :: ['blood flow velocities', 'BFVs']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['ischemic infarctions']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['Orthostatic hypotension']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: @entity1877 kinase is the first enzyme in the @entity13667 - @entity1877 pathway that synthesizes @entity2434 , the major phospholipid in eukaryotic cell membranes. In @entity1 , @entity1877 kinase exists as three isoforms (CKa1, a2, and b). Specific inhibition of CKa has been reported to selectively kill tumoral cells. Monoclonal and polyclonal antibodies against CKa used in previous studies to detect the level of this isozyme in different cellular or biochemical contexts were able to detect either the a1 or the a2 isoform. METHODOLOGY/PRINCIPAL FINDINGS: In this study, an antiserum against CKa was produced by immunizing @entity95 with denatured, purified recombinant CKa2 full-length protein. This antiserum was highly specific for CKa when tested with extracts from different cell lines, and there was no cross reactivity with purified @entity9055 and other related proteins like @entity1 @entity8398 kinases (EK) and @entity375 @entity1877 or @entity8398 kinases. The antiserum simultaneously detected both CKa1 and a2 isoforms in MCF-7 and HepG2 cell extracts, but not in HeLa, HCT-116, and @entity19 embryonic stem cell extracts. Subsequent protein dot blot assay of total CKa in a @entity1 normal/ @entity5 protein array of 30 tissue samples by using the antiserum showed that CKa was not overexpressed in all @entity5 tissues when compared to their normal counterparts. Most striking differences between @entity5 and normal CKa expression levels were observed in kidney (11-fold higher in @entity5 ) and liver (15-fold lower in @entity5 ) samples. CONCLUSION/SIGNIFICANCE: Apart from its high sensitivity and specificity, the antiserum produced in this work, which does not require further purification, has the advantage of co-detecting both a1 and a2 isoforms in cell extracts for direct comparison of their expression levels.

title: Highly specific antibodies for co-detection of XXXX @entity1877 kinase a1 and a2 isoforms.

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'human']

entities_list: @entity8398 :: ('MESH:D019856', 'Chemical') :: ['ethanolamine']

entities_list: @entity2434 :: ('MESH:D010713', 'Chemical') :: ['phosphatidylcholine']

entities_list: @entity1877 :: ('MESH:D002794', 'Chemical') :: ['choline', 'Choline']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: BACKGROUND: Juvenile recurrent @entity8174 (JRP) is a rare, recurrent non-obstructive, nonsuppurative parotid inflammation in young @entity1 with a multifactorial etiology. METHODS: The records of 12 @entity1 with recurrent @entity8174 were retrospectively reviewed. RESULTS: The age of onset ranged from 3 to 8 years (mean, 5.1 years). Each attack lasted an average of 3.5 days. The major clinical manifestations included @entity221 (75%), swelling (100%), and @entity158 (100%). One @entity1 also had @entity2133 and @entity9849 sicca. Her biopsy specimen from a minor salivary gland was consistent with juvenile Sjiigren's syndrome. Six @entity1 had positive antinuclear antibodies (4 with a speckled pattern and 2 each with a homogeneous or nucleolar pattern). Bilateral sialography was performed in 9 @entity1 . The results in 4 were normal, 2 had unilateral punctate sialectasis, and 3 had bilateral sialectasis. After sialography, the frequency of recurrences significantly decreased from 5.11 to 0.56 per year (P < 0.05). CONCLUSIONS: Bilateral sialography is useful for the diagnosis of JRP, but it also appears to decrease the frequency of recurrences.

title: Juvenile recurrent XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'girl', 'patients']

entities_list: @entity8174 :: ('MESH:D010309', 'Disease') :: ['parotitis']

entities_list: @entity2133 :: ('MESH:D014987', 'Disease') :: ['xerostomia']

entities_list: @entity9849 :: ('MESH:D007637', 'Disease') :: ['keratoconjunctivitis']

answer: @entity8174 :: (MESH:D010309,Disease) :: ['parotitis']


abstract: BACKGROUND: The identification of new @entity5 -associated antigens and epitopes is the prerequisite for @entity5 immunotherapy. The @entity1 telomerase catalytic subunit @entity1 @entity2215 ( @entity2215 ) is an attractive target for @entity5 therapy. The @entity2215 :540-548 peptide (p540, ILAKFLHWL) was previously identified as an @entity1529 *0201-restricted T-cell epitope. However, other MHC-restricted epitopes in this antigen are urgently needed for an effective T-cell-based @entity5 treatment. The goal of this study was to identify other immunogenic peptides of @entity2215 restricted by @entity1529 *0201 molecule, which accounts for about 15% of the Chinese population. METHODS: Computer algorithms were used for epitope prediction, followed by analyzation on the plate of Discovery Studio 2.5. The candidate peptides were verified by T2-cell-binding assay, ELISPOT analysis, flow cytometry examination, and in vitro and in vivo @entity5 inhibition assay. RESULTS: Six peptides were predicted by computer algorithms. Of these peptides, p540 and p675 (LLGASVLGL) were identified with lower binding free energies than the other four peptides, binding to @entity1529 *02 more strongly, and elicited stronger IFN-y secretion of @entity1 ' peripheral blood mononuclear cells. The CTL clone against p675 elicited a significant @entity5 cell inhibition effect @entity1529 *0201 restrictly. CONCLUSIONS: We identified p675 as a new @entity1529 *0201-restricted T-cell epitope, and the CTL clone against it could suppress @entity5 growth effectively.

title: Identification of a new cytotoxic T-cell epitope p675 of @entity1 XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity2215 :: ('7015', 'Gene') :: ['hTERT', 'telomerase reverse transcriptase']

answer: @entity2215 :: (7015,Gene) :: ['telomerase reverse transcriptase']


abstract: Blastic @entity5 ( @entity5 ) is still poorly understood. We describe a cohort of 23 Roswell Park Cancer Institute (RPCI) @entity1 and 89 additional cases from the English literature for whom biologic features were described. We initially compared our 23 @entity1 to the 89 cases from the literature. Our population had significantly less @entity1 with prior history of @entity4406 ( @entity4406 ), shorter time from @entity5 diagnosis to blastic transformation, <3 prior therapies, more frequent use of @entity1862 and @entity1307 and less frequent use of alkylating agents. Interestingly, the overall survival of the two cohorts from the time of blastic transformation was similar. We therefore looked at the outcome of the entire cohort (n=112). @entity1 with prior history of essential @entity1148 survived longer than @entity1 with prior history of @entity4018 or @entity4406 . Further, @entity1 with <3 prior therapies, those who lacked complex karyotype and those <60 year old at @entity5 diagnosis had significantly longer survival. Among the PRCI population, 20/23 @entity1 underwent induction treatment with @entity2592 and an @entity4349 containing regimens; 12 achieved remission and their overall survival was significantly longer than those who did not. Three @entity1 underwent an allogeneic transplantation and their survival was significantly longer than those who did not. @entity1 with <3 prior therapies, those who lack complex karyotype and those <60 at @entity5 diagnosis have longer survival following blastic transformation. Finally, allogeneic transplantation represents the only chance for long-term survival in these @entity1 .

title: Myeloid blastic XXXX --a review of 112 cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1148 :: ('MESH:D013922', 'Disease') :: ['thrombocythemia']

entities_list: @entity4349 :: ('CHEBI:48120', 'Chemical') :: ['anthracycline']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['transformation of myeloproliferative neoplasms', 'MPN']

entities_list: @entity1862 :: ('MESH:D006918', 'Chemical') :: ['hydroxyurea']

entities_list: @entity1307 :: ('2056', 'Gene') :: ['erythropoietin']

entities_list: @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine']

entities_list: @entity4018 :: ('MESH:D055728', 'Disease') :: ['myelofibrosis']

entities_list: @entity4406 :: ('MESH:D011087', 'Disease') :: ['PV', 'polycythemia vera']

answer: @entity5 :: (MESH:D009369,Disease) :: ['transformation of myeloproliferative neoplasms']


abstract: Most previously reported individuals with @entity117 ( @entity117 , @entity1281 )-induced @entity565 have been adults. This study was undertaken to define the prevalence of @entity1281 intolerance among @entity1 with intractable @entity565 . Fifty @entity1 (34 @entity1 and 16 @entity1 ) ranging in age from 6 to 18 years with extrinsic (atopic) @entity565 were studied. None had a history of @entity1281 sensitivity or nasal polyps; all required continuous medication including cromolyn @entity1372 and daily or intermittent @entity230 . Anti-asthmatic medications were stopped 12 hours prior to testing. At the same time of day, each subject, in a doubleblind manner, on two separate days, ingested either 300 mg of @entity1281 or 100 mg of @entity1132 (placebo). Measurements of FVC, FEV1, and FEF25-75 were obtained prior to challenge and one half, one, two, three, and four hours after. @entity1281 intolerance required a decrease of 30% in lung function with @entity1281 as compared to placebo. Fourteen of 50 (28%) were @entity1281 -intolerant; a greater number were @entity1 , and they had more @entity1244 and an onset of disease prior to 2 years of age. Steroid dependency, frequency of @entity484 , nasal @entity1712 , serum IgE levels, and peripheral eosinophil counts did not differ between the two groups. The use of @entity117 in childhood @entity565 should be limited.

title: @entity117 intolerance in chronic childhood XXXX : Detected by oral challenge.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'girls', 'boys']

entities_list: @entity1244 :: ('MESH:D012852', 'Disease') :: ['sinusitis']

entities_list: @entity1712 :: ('MESH:D004802', 'Disease') :: ['eosinophilia']

entities_list: @entity117 :: ('MESH:D001241', 'Chemical') :: ['acetylsalicylic acid', 'aspirin']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

answer: @entity565 :: (MESH:D001249,Disease) :: ['asthma']


abstract: Intradural spinal @entity145 with @entity1745 are rare. When becoming symptomatic they cause variable symptoms involving gait disturbance, paraparesis or @entity10492 and @entity9 , decreasing significantly the @entity1 ' life quality. The extension of such cysts averages 3.7 vertebral bodies. The diagnosis is clinical and radiological with the use of MRI, CT myelography or a combination of both. The best treatment option is complete removal of the cyst. However, even when paresis is regressing there is no good recovery from @entity9 . Laminectomy approach can cause @entity260 especially when the cyst(s) expand(s) in more than one level. Alternatively, a cyst fenestration can be performed, including the levels of the maximal @entity1745 . The clinical outcome is as good as after the cyst resection enabling the @entity1 to walk again. The @entity9 may persist and require medication. A clinical case is presented, and the literature is reviewed. In the present case we report a @entity1 with intradural @entity145 extending from T6 to L2 and causing severe @entity11583 as well as @entity9 and hypaesthesia. The spinal-cord was compressed at T8 and T12. Surgical treatment with partial cyst resection in the compressed levels with an interlaminar approach brought similar results as complete resection. The @entity1 was able to walk without help which was not possible before surgery. The cysts' extension is impressive as well as the minimal operative procedure.

title: XXXX caused by idiopathic intradural @entity145 of the spine: review of the literature and illustrated case.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity11583 :: ('MESH:D020234', 'Disease') :: ['gait ataxia']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications']

entities_list: @entity145 :: ('MESH:D016080', 'Disease') :: ['arachnoid cysts']

entities_list: @entity1745 :: ('MESH:D013117', 'Disease') :: ['spinal cord compression', 'cord compression']

entities_list: @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain']

entities_list: @entity10492 :: ('MESH:C565722', 'Disease') :: ['tetraparesis']

answer: @entity1745 :: (MESH:D013117,Disease) :: ['Spinal cord compression']


abstract: PURPOSE: @entity2649 ( @entity2649 ), a @entity179 encountered in adults > 65 years, is a leading cause of back and lower extremity @entity158 , @entity425 , @entity73 sensation and balance. The purpose of this pilot study was to determine whether @entity1 with @entity2649 demonstrate increased postural sway and @entity73 balance, compared to healthy counterparts. METHODS: @entity1 with varying severity of @entity2649 and age and gender matched controls were recruited from a tertiary care hospital, yielding 6 case-control pairs. Subjects completed generic health status (SF-36), disease specific scales ( @entity2649 ) and demographic forms. Medical comorbidities were extracted from medical records. @entity1 received a musculoskeletal examination and performed the Functional Reach (FR) and Timed "Up _ Go" (TUG) tests. Stabilogram diffusion analysis (SDA) measured center of pressure (COP). RESULTS: @entity1 reported moderately @entity73 physical function, lumbar flexibility and walked with a slightly wider base of support. TUG scores did not differ across groups. Significantly limited FR scores indicated that @entity1 had @entity73 dynamic balance and were at a greater risk of falls. SDA demonstrated no significant difference in sway for @entity1 and controls; however, @entity1 demonstrated significantly higher critical values for antero-posterior (AP) displacement than controls. CONCLUSION: @entity1 with @entity2649 , even those with mild symptoms, demonstrate decreased function and balance, particularly in the AP direction. Physical examination measures and TUG are not adequate to assess @entity73 or risk of falls in these @entity1 . Measures such as the FR and SDA may be useful in detecting the aspects of @entity73 perceived by @entity1 .

title: Pilot case control study of postural sway and balance performance in aging adults with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity2649 :: ('MESH:C563613', 'Disease') :: ['Lumbar spinal stenosis', 'LSS']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['impaired', 'balance impairments']

entities_list: @entity425 :: ('MESH:D018908', 'Disease') :: ['weakness']

entities_list: @entity179 :: ('MESH:D019636', 'Disease') :: ['degenerative disease']

answer: @entity2649 :: (MESH:C563613,Disease) :: ['degenerative lumbar spinal stenosis']


abstract: OBJECTIVES: To determine recurrence patterns and survival outcomes of stage II uterine @entity1377 (UPSC) @entity1 treated by various modalities with an emphasis on @entity3003 / @entity1311 -based chemotherapy (CT)+/-radiotherapy (RT). METHODS: A retrospective, multi-institution study of @entity1 with stage II UPSC diagnosed from 1992 to 2006 was performed. All @entity1 underwent comprehensive surgical staging. Treatment included observation (OBS), RT (vaginal brachytherapy, whole pelvic and/or whole abdominal therapy), or >or=3 cycles @entity3003 / @entity1311 alone or with RT. Recurrence and survival outcomes were determined. RESULTS: We identified 55 subjects: 10 treated with OBS, 26 with RT alone and 19 with CT+/-RT. After a median follow-up of 33 mos (range, 10-119), 20 recurrences (36%) were observed. There was an overall difference in recurrence based upon treatment (p=.013). Specifically, all CT+/-RT treated @entity1 had a lower risk of recurrence (11%) compared to @entity1 treated by RT alone (50%) or OBS (50%). No @entity1 treated with both CT+RT (n=12) experienced a recurrence. Treatment with CT was also associated with a decreased risk of recurrence on multivariate analysis (p=.015). Most recurrences were extra-pelvic (70%), occurred within 2 years (85%) and were not salvageable (84%). Five-year progression-free survival was 86% in chemotherapy-treated @entity1 versus 41% in those not receiving chemotherapy (p=.010); overall survival was 88% in chemotherapy-treated @entity1 versus 64% in those not receiving chemotherapy (p=.115). CONCLUSIONS: Stage II UPSC @entity1 have a significant risk for unsalvageable, extra-pelvic recurrence. However, treatment with @entity902 / @entity3907 therapy+/-RT appears to reduce this risk and is associated with improved progression free survival outcomes.

title: Stage II uterine @entity1377 : @entity3003 / XXXX chemotherapy improves recurrence and survival outcomes.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity1377 :: ('MESH:D002291', 'Disease') :: ['papillary serous carcinoma']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel']

entities_list: @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']

answer: @entity1311 :: (MESH:D017239,Chemical) :: ['paclitaxel']


abstract: OBJECTIVES: to assess the role of @entity8 ( @entity8 ) in the characterization of focal @entity409 (FLLs) incidentally discovered but indeterminate at gray-scale ultrasound (US). MATERIALS AND METHODS: one hundred forty-two consecutive @entity1 with 174 FLLs (169 benign and 5 malignant) incidentally discovered but indeterminate at gray-scale US, underwent @entity8 after the administration of SonoVue. Two readers independently reviewed @entity8 scans and: (1) classified each lesion as malignant or benign on a 5-point scale of confidence by means of definite diagnostic criteria; (2) provided if possible a specific diagnosis; (3) were requested if further imaging was needed for lesion characterization. Sensitivity, specificity, and areas under the receiver-operating characteristic curve (Az) as well as interobserver agreement were calculated. RESULTS: at @entity8 , both readers correctly differentiated benign from malignant lesions in 168 of 174 (96.5%) cases (P < 0.0001). A specific correct diagnosis was provided in 123 of 174 (70.7%) and 127 of 174 (72.9%) cases for reader 1 and 2, respectively (P < 0.0001). A further imaging study to characterize the lesion after @entity8 was requested in 67 cases (38.5%) for reader 1 (P < 0.001) and 46 cases (26.4%) for reader 2 (P < 0.001). Receiver-operating characteristic analysis after @entity8 revealed Az value of 1 for both readers and sensitivity and specificity values of 100% and 97.04% for reader 1 and 100% and 96.45 for reader 2 respectively (P < 0.0001). Inter-reader agreement at @entity8 was good (weighted k = 0.779). CONCLUSION: @entity8 improves the diagnostic performance of radiologists in the characterization of indeterminate FLLs incidentally discovered at US and reduces the need for further radiologic work-up.

title: Indeterminate focal XXXX incidentally discovered at gray-scale US: role of contrast-enhanced sonography.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['CEUS', 'contrast-enhanced ultrasound']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver lesions']

answer: @entity409 :: (MESH:D008107,Disease) :: ['liver lesions']


abstract: The discovery that aerobic exercise increases adult hippocampal neurogenesis and can enhance cognitive performance holds promise as a model for regenerative medicine. This study adds two new pieces of information to the rapidly growing field. First, we tested whether exercise increases vascular density in the granular layer of the dentate gyrus, whole hippocampus, and striatum in C57BL/6J @entity19 known to display procognitive effects of exercise. Second, we determined the extent to which new neurons from exercise participate in the acute neuronal response to high levels of running in B6D2F1/J (F1 hybrid of C57BL/6J female by @entity7840 /2J male). @entity19 were housed with or without a running wheel for 50 days (runner vs. sedentary). The first 10 days, they received daily injections of @entity1603 to label dividing cells. The last 10 days, @entity19 were tested for performance on the Morris water maze and rotarod and then euthanized to measure neurogenesis, @entity9830 induction from running and vascular density. In C57BL/6J, exercise increased neurogenesis, density of blood vessels in the dentate gyrus and striatum (but not whole hippocampus), and enhanced performance on the water maze and rotarod. In B6D2F1/J, exercise also increased hippocampal neurogenesis but not vascular density in the granular layer. Improvement on the water maze from exercise was marginal, and no gain was seen for rotarod, possibly because of a ceiling effect. Running increased the number of @entity9830 positive neurons in the granular layer by fivefold, and level of running was strongly correlated with @entity9830 within 90 min before euthanasia. In runners, approximately 3.3% (+/-0.008 S.E.) of @entity1603 -positive neurons in the middle of the granule layer displayed @entity9830 when compared with 0.8% (+/-0.001) of @entity1603 -negative neurons. Results suggest that procognitive effects of exercise are associated with increased vascular density in the dentate gyrus and striatum in C57BL/6J @entity19 , and that new neurons from exercise preferentially function in the neuronal response to running in B6D2F1/J.

title: Functional analysis of neurovascular adaptations to exercise in the dentate gyrus of young adult XXXX associated with cognitive gain.

answer: @entity19 :: (10090,Species) :: ['mice']


abstract: BACKGROUND: Favorable outcomes in @entity4924 are predicated on tricuspid valve competence and right ventricular function. Successful valve repair should be aggressively pursued to avoid the morbidity of prosthetic tricuspid valve replacement. We report our experience with valve-sparing intracardiac repair, emphasizing novel concepts and techniques of valve repair supplemented by selective bidirectional Glenn (BDG). METHODS: Between June 1993 and December 2008, 57 nonneonatal @entity1 underwent @entity4924 repairs. The median age at operation was 8.1 years. All were symptomatic in New York Heart Association (NYHA) functional class II (n = 38), III (n = 17), or IV (n = 1). Preoperatively, 26 had mild or moderate @entity848 at rest. We used a number of valve reconstructive techniques that differed substantially from those currently described. BDG was performed in 31 @entity1 (55%) who met specific criteria. RESULTS: No early or late @entity204 occurred. At the initial repair, 3 @entity1 received a prosthetic valve. Four @entity1 required reoperation for severe @entity997 . Repeat repairs were successful in 2 @entity1 . At follow-up (range, 3 months to 6 years), all @entity1 were acyanotic and in NYHA class I. @entity997 was mild or less in 49 (86%) and moderate in 6 (11%). Freedom from a prosthesis was 91% (52 of 57). CONCLUSIONS: Following a protocol using BDG for ventricular unloading in selected @entity1 with @entity4924 can achieve a durable valve-sparing repair using the techniques described. Excellent functional midterm outcomes can be obtained with a selective one and a half ventricle approach to @entity4924 .

title: Selective right ventricular unloading and novel technical concepts in XXXX .

entities_list: @entity997 :: ('MESH:D014262', 'Disease') :: ['Tricuspid regurgitation', 'tricuspid regurgitation']

entities_list: @entity4924 :: ('MESH:D004437', 'Disease') :: ["Ebstein's anomaly"]

entities_list: @entity848 :: ('MESH:D003490', 'Disease') :: ['cyanosis']

answer: @entity4924 :: (MESH:D004437,Disease) :: ['Ebstein's anomaly']


abstract: BACKGROUND: Five to 10  % of @entity1 with @entity521 present with symptoms of epidural compression (EC). More than half these @entity1 are diagnosed in the first year of life. The case of a @entity521 presenting symptoms of EC at birth is exceptional and deserves to be reported. CASE PRESENTATION: We describe a case of female born at the 36(th) week of pregnancy by caesarian section decided following ultrasonographic discovery of oligohydramnios. At birth, she was noted to have motor deficit involving both legs and continuous urinary dripping. These symptoms were found to be secondary to a @entity521 infiltrating the spinal canal. @entity5 responded well to chemotherapy, but neurologic deficit only slightly improved and @entity1494 remained unchanged. At 2  years of age, @entity1 is able to walk with help of leg orthoses, suffers chronic @entity1142 requiring daily medications, and has @entity16 necessitating multiple daily catheterizations. CONCLUSIONS: The finding of a newborn presenting with symptoms of EC secondary to a @entity521 invading the spinal canal is quite uncommon. The case described herewith confirms that these rare @entity1 have an excellent survival probability, but almost always develop severe functional sequelae.

title: XXXX presenting with symptoms of epidural compression at birth: a case report.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient']

entities_list: @entity1494 :: ('MESH:D001745', 'Disease') :: ['bladder dysfunction']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurologic bladder']

entities_list: @entity521 :: ('MESH:D009447', 'Disease') :: ['neuroblastoma', 'paraspinal neuroblastoma']

entities_list: @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation']

answer: @entity521 :: (MESH:D009447,Disease) :: ['Neuroblastoma']


abstract: BACKGROUND: There is a paucity of data on outcomes in @entity1 undergoing percutaneous coronary intervention (PCI) for @entity583 ( @entity583 ) caused by left main stem (LMS) @entity715 . OBJECTIVES: We sought to determine (i) the clinical features, (ii) correlates of early mortality, and (iii) long-term outcomes in contemporary @entity1 undergoing primary PCI for unprotected LMS @entity715 . METHODS: From 1,115 consecutive primary PCI cases at two tertiary referral centers between January 2004 and September 2007, 28 cases (2.5%) with unprotected LMS culprit lesions were identified. Data were obtained from review of institutional databases, folder audit, telephone survey of @entity1 , and independent review of angiograms. RESULTS: The mean age of @entity1 was 68 +/- 14 years. Males comprised 76%, and 21% had @entity6 . Significant morbidity was noted at presentation: shock in 18 (62%), @entity4 in 15 (52%), and @entity1167 in 10 (35%) @entity1 , respectively. Lesion location was ostial in 7 (25%), body in 8 (29%), and distal in 13 (46%) @entity1 , respectively. Angiographic success was achieved in 24 @entity1 (83%). Stents were deployed in 27 @entity1 (96%); drug-eluting stents in 11 @entity1 (39%). No @entity1 required in-hospital CABG. Cumulative in-hospital mortality was 36%. Univariate predictors of in-hospital mortality included shock, preceding @entity1167 , and angiographic failure (all P < 0.05). At a mean follow-up of 26 +/- 12 months in hospital survivors, there were two TVR (elective CABGs), one @entity204 , and no reinfarctions. CONCLUSION: We report a lower than previously reported in-hospital mortality of 36% in contemporary @entity1 undergoing primary PCI for unprotected LMS @entity715 . Long-term outcomes in hospital survivors appear favorable.

title: Primary percutaneous coronary intervention for XXXX caused by unprotected left main stem @entity715 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['pulmonary oedema']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiac arrest']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['AMI', 'acute myocardial infarction']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

answer: @entity583 :: (MESH:D009203,Disease) :: ['acute myocardial infarction']


abstract: BACKGROUND: @entity28 is considered a low-grade inflammatory state and has been associated with increased acute phase proteins as well as changes in serum @entity1718 . Few studies have assessed associations between acute phase proteins and serum @entity1718 in morbidly @entity28 @entity1 . OBJECTIVE: To investigate the relationship between acute phase proteins ( @entity1851 , Orosomucoid, and Albumin) and serum @entity1718 in morbidly @entity28 @entity1 . METHODS: Twenty-two morbidly @entity28 @entity1 were enrolled in this study. Biochemical and clinical data were obtained before bariatric surgery, and @entity1718 measured in preoperative serum. RESULTS: Orosomucoid was negatively correlated with @entity27146 (P = 0.027) and @entity7784 ( @entity8393 ) (P = 0.037) and positively with @entity1426 (AA) (P = 0.035), AA/ @entity8393 ratio (P = 0.005), and n-6/n-3 @entity1474 ratio (P = 0.035). @entity1851 ( @entity1851 ) was negatively correlated with @entity27146 (P = 0.048), and both @entity1851 and @entity1851 /Albumin ratio were negatively correlated with @entity31276 (P = 0.010, P = 0.008, resp.). Albumin was positively correlated with @entity8393 (P = 0.027) and @entity31276 (P = 0.008). Other correlations were not statistically significant. CONCLUSION: Our findings suggest that serum @entity1718 are linked to acute phase proteins in morbidly @entity28 @entity1 .

title: Relationship between acute phase proteins and serum fatty acid composition in morbidly @entity28 XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity7784 :: ('MESH:D015118', 'Chemical') :: ['eicosapentaenoic acid']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['Obesity', 'obese']

entities_list: @entity1426 :: ('MESH:D016718', 'Chemical') :: ['arachidonic acid']

entities_list: @entity1474 :: ('MESH:D005231', 'Chemical') :: ['polyunsaturated fatty acids']

entities_list: @entity27146 :: ('MESH:C030358', 'Chemical') :: ['lauric acid']

entities_list: @entity31276 :: ('MESH:C013102', 'Chemical') :: ['margaric acid']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['CRP', 'C-Reactive Protein']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: (90)Y radioembolization (selective internal radiation therapy [SIRT]) has emerged as a valuable therapeutic option in unresectable, chemotherapy-refractory hepatic @entity3 from @entity0 . The objective of the present study was to evaluate @entity419 PET/CT for predicting survival in these @entity1 . METHODS: Fifty-eight consecutive @entity1 with hepatic @entity3 from @entity0 were treated with SIRT. Before therapy, all @entity1 underwent MRI of the liver. @entity419 PET/CT was performed at baseline and 3 mo after SIRT to calculate percentage changes in maximum @entity419 standardized uptake value (SUV(max)) relative to baseline. A decrease of more than 30% in the follow-up scan, compared with the baseline examination, indicated therapy response. Treatment response at 3 mo was also assessed in 43 @entity1 using contrast-enhanced MRI and CT on the basis of the Response Evaluation Criteria in @entity5 . All @entity1 were followed to complete survival data. RESULTS: Overall median survival after SIRT was 47 wk. Response as assessed with SUV(max) correlated significantly with survival after radioembolization, with responders having significantly longer survival (65 wk) than nonresponders (43 wk; P < 0.05). In multivariate analysis the change in SUV(max) was identified as the only independent predictor of survival (hazard ratio, 0.23; P < 0.005). Furthermore, a high pretherapeutic SUV(max) (>20) was associated with a significantly shorter median survival than was an SUV(max) of 20 or less (21 vs. 52 wk; P < 0.005). The presence of extrahepatic @entity3 (mean survival in both groups, 47 wk; P = 0.92), hormone receptor status ( @entity172 , P = 0.53; @entity1420 , P = 0.79; @entity1722 , P = 0.49), and MRI/CT response (P = 0.91) did not predict survival. CONCLUSION: The change in SUV(max) as assessed by @entity419 PET/ @entity16178 mo after SIRT was identified as the only independent predictor of survival in @entity1 with hepatic @entity3 of @entity0 .

title: @entity419 PET/CT predicts survival after radioembolization of hepatic XXXX from @entity0 .

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Solid Tumors']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

answer: @entity3 :: (MESH:D009362,Disease) :: ['metastases']


abstract: BACKGROUND: Relatively low rates of chemotherapy receipt have been observed in older @entity1 diagnosed with advanced @entity1149 ( @entity1149 ) in SEER-Medicare-based studies. However, little is known about variation in first-line @entity1149 chemotherapy use in younger @entity1 , health maintenance organization (HMO)-based settings, and for high-cost, novel agents, such as bevacizumab and @entity3866 . METHODS: A cohort of 6614 stage IIIB/IV @entity1149 @entity1 aged >=  21 years diagnosed between 2000 and 2007 was identified at four HMOs that participate in the @entity5 ( @entity5 ). Demographic, comorbidity, @entity5 characteristics, and chemotherapy treatment data were included in logistic regression models to identify factors associated with chemotherapy receipt and tests of association examined secular and age-specific variation in first-line chemotherapy regimens. RESULTS: Within 120 days of diagnosis, 3612 (55%) @entity1 received chemotherapy; increasing from 52% of @entity1 diagnosed in 2000 to 59% in 2007 (p<0.001). Receipt was significantly higher for @entity1 aged <65 years (64% versus 46% in >=  65) and was inversely related to stage and comorbidites (all p<0.001). @entity3003 and @entity1311 were received most frequently. @entity3866 and bevacizumab use in the later years of the study was associated with a significant change in distributions of first-line chemotherapies (p<0.001). CONCLUSIONS: For @entity1 alive 30 days post diagnosis, chemotherapy use was higher in the aged population (>65 years) than previously published estimates, and higher still among younger @entity1 . Chemotherapy use increased over the observation period, and the mix of first-line therapies used changed substantially over time. Of note, novel, high cost treatments were used in first-line therapy prior to FDA approval, increasing significantly throughout the study period. These findings demonstrate the utility of HMO @entity5 data to augment SEER-Medicare to conduct comparative effectiveness research related to chemotherapy use and the use of specific agents, especially among younger @entity1 .

title: Patterns and predictors of first-line chemotherapy use among adults with advanced XXXX in the @entity5 research network.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'CRN', 'Cancer Research Network']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['Carboplatin']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel']

entities_list: @entity3866 :: ('MESH:C400278', 'Chemical') :: ['erlotinib', 'Erlotinib']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']


abstract: INTRODUCTION: @entity8619 ( @entity8619 ) is a relatively common, chronic immune-mediated disease. The main treatment for @entity8619 has been the administration of topical or systemic @entity288 , but side effects have limited their use. We aimed to assess the effect and adverse reaction of @entity2585 ( @entity2585 ) in combination with @entity288 for the treatment of @entity8619 . METHODS: Eighty one @entity1 with a confirmed clinical and histopathologic diagnosis of @entity8619 (44 @entity2363 [ @entity2363 ] @entity1 , 37 erythematous/erosive @entity8619 [EOLP] @entity1 ) were enrolled. @entity1 were treated with topical or systemic @entity288 , with or without 1200mg @entity2585 in the @entity2363 and EOLP groups, respectively. @entity1 were followed for 6months. The @entity158 and severity of the lesions were recorded at the initial visit and monthly thereafter during the follow-up period. RESULTS: Seventy three of 81 @entity1 completed the scheduled treatment period. In the @entity2363 @entity1 group, combined treatment significantly reduced the visual analogue scale (VAS) at months 3, 5, and 6. The clinical signs (CS) of @entity2363 @entity1 worsened during the follow-up period in control group. However, CS in the combined treatment group remained largely unchanged at months 4-6. In the EOLP @entity1 group, the VAS decreased almost equally in @entity1 with and without combined treatment at months 1-2, but continued to significantly decrease in the combined treatment group in months 4-6. The CS of the combined treatment group decreased gradually over time in the study period, with significantly lower scores in the treatment versus control group (which decreased slightly in the first three months, then remained almost unchanged during the following visits). The effective rates of combined treatment were statistically higher versus control groups both in @entity2363 and EOLP @entity1 . CONCLUSIONS: @entity2585 is a safe and effective drug for @entity8619 with rare side effects. Combined treatment of @entity2585 with @entity288 shows a definite therapeutic effect. More than four months of medical treatment of @entity2585 is recommended to achieve the full effect.

title: Clinical observation on the treatment of oral lichen planus with XXXX combined with @entity288 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity2585 :: ('MESH:D002062', 'Disease') :: ['total glucosides of paeony capsule', 'TGPC']

entities_list: @entity2363 :: ('MESH:C538361', 'Disease') :: ['reticular OLP', 'ROLP']

entities_list: @entity8619 :: ('MESH:D017676', 'Disease') :: ['OLP', 'Oral lichen planus']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity2585 :: (MESH:D002062,Disease) :: ['total glucosides of paeony capsule']


abstract: @entity14534 is a novel, oral reversible direct @entity556 inhibitor that is rapidly absorbed and converted to its active form, @entity3926 . @entity3926 has been shown to be a potent, competitive, and reversible inhibitor of @entity556 , inhibiting both @entity556 activity and generation. Studies in healthy volunteers and in @entity1 undergoing orthopedic surgery indicate that @entity3926 has a predictable pharmacokinetic profile, allowing for a fixed-dose regimen without the need for coagulation monitoring. In healthy volunteers, peak plasma concentrations of @entity3926 are reached approximately 2 hours after oral administration. The elimination half-life is 12 to 14 hours, with clearance predominantly occurring via renal excretion of unchanged drug. @entity3926 is not metabolized by cytochrome P450 isoenzymes, has no interactions with food, and also has a low potential for drug-drug interactions. The pharmacokinetic profile of @entity3926 is consistent across a broad range of different @entity1 populations and is unaffected by gender, body weight, ethnic origin, @entity28 , and mild-to-moderate @entity409 . Small differences in @entity3926 pharmacokinetics associated with age are attributable to variation in renal function. @entity14534 produces a predictable pharmacodynamic effect and requires no coagulation monitoring. It has been approved in the European Union (EU) and Canada for prophylaxis of @entity1031 in @entity1 undergoing total knee or hip arthroplasty. Ongoing clinical trials are investigating its use in the treatment of @entity1211 , prevention of @entity64 in @entity1 with nonvalvular @entity955 , and treatment of @entity1031 complications, following acute @entity301 .

title: Pharmacology, pharmacokinetics, and pharmacodynamics of XXXX , an oral direct @entity556 inhibitor.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary syndromes']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['hepatic impairment']

entities_list: @entity3926 :: ('MESH:C554682', 'Chemical') :: ['Dabigatran', 'dabigatran']

entities_list: @entity14534 :: ('MESH:C453962', 'Chemical') :: ['Dabigatran etexilate']

entities_list: @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolism', 'thromboembolic']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['venous thromboembolism']

answer: @entity14534 :: (MESH:C453962,Chemical) :: ['dabigatran etexilate']


abstract: UNASSIGNED: Enteroaggregative @entity526 (EAEC) bears remarkable capacity to adhere the host intestinal mucosal surface and results in acute or persistent childhood @entity294 worldwide. In this study, an attempt has been made to inhibit EAEC cell adherence in-vitro using synthetic peptides. @entity526 isolates (n  =  54) were isolated from the stool samples of clinically diagnosed pediatric diarrheal @entity1 . 92.8% isolates showed different types of aggregative adherence patterns with HEp-2  cells. AAF-II (Aggregative Adherence Fimbriae-II) EAEC exhibited the maximum ability to form biofilm and intracellular survival. Peptides were designed against the high antigenic epitopic regions of AAF-II adhesin of EAEC O42 using prediction algorithms like BcePred and ProPred software to block the EAEC cell adhesion in-vitro. Peptides @entity18907 (MRIKAWGEANHGQL) demonstrated higher inhibition of EAEC cell adhesion than P1 (GMQGSITPAIPLRPG). Interestingly, increasing the pre-incubation time of the peptides with HEp-2  cells from 1  h to 2  h showed the maximum inhibition. The data suggested the potential role of P2 and P3 peptides in successfully blocking the binding of AAF-II EAEC with HEp-2  cell receptors. Hence, the peptides may be efficacious in designing new chemothrapeutic for the management of EAEC mediated @entity294 .

title: Inhibition of enteroaggregative XXXX cell adhesion in-vitro by designed peptides.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity18907 :: ('5394', 'Gene') :: ['P2 (DITITPATNRDVNV) and P3']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli', 'E. coli']

answer: @entity526 :: (562,Species) :: ['Escherichia coli']


abstract: @entity174 of the proximal tibia comprise a huge spectrum of injuries with different @entity174 configurations. The combination of tibia @entity174 with diaphyseal extension is a rare injury with sparse literature being available on treatment of the same. Various treatment modalities can be adopted with the aim of achieving a well-aligned, congruous, stable joint, which allows early motion and function. We report a case of a 40-year-old male who sustained a Schatzker type VI @entity174 of left tibial plateau with diaphyseal extension. On further investigations, the @entity1 was diagnosed to have @entity6 with grossly deranged blood sugar levels. The depressed tibial condyle was manipulated to lift its articular surface using K-wire as a joystick and stabilized with an additional K-wire. Distal tibial skeletal traction was maintained for three weeks followed by an above knee cast. At eight months of follow-up, X- @entity16039 revealed a well-consolidated @entity174 site, and the @entity1 had attained a reasonably good range of motion with only terminal restriction of squatting. @entity174 with diaphyseal extension in a @entity1 with uncontrolled @entity6 is certainly a challenging entity. After an extended search of literature, we could not find any reports highlighting a similar method of treatment for complex tibial @entity130 in a @entity1 with uncontrolled @entity6 .

title: Minimally Invasive Treatment of a Complex Tibial Plateau Fracture with Diaphyseal Extension in a @entity1 with Uncontrolled XXXX : A Case Report and Review of Literature.

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['plateau fracture', 'Tibial plateau fractures', 'Fractures', 'fracture']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['plateau injuries']

answer: @entity6 :: (MESH:D003920,Disease) :: ['Diabetes Mellitus']